Operating
Change in Accrued Liabilities
Kailera Therapeutics Change in Accrued Liabilities increased by 788.7% to $9.38M in Q1 2026 compared to the prior quarter.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026May 26, 2026
How to read this metric
An increase represents a source of cash through deferred payment, while a decrease represents a cash outflow as obligations are settled.
Detailed definition
Reflects the change in obligations for expenses incurred but not yet invoiced or paid, such as employee compensation, ta...
Peer comparison
Standard operating cash flow component found in almost all corporate financial statements.
Metric ID:
change_in_accrued_liabilitiesHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $1.06M | $9.38M |
| QoQ Change | — | +788.7% |
| YoY Change | — | +788.7% |
Range$1.06M – $9.38M
Avg YoY Growth+788.7%
Median YoY Growth+788.7%
Change in Accrued Liabilities at Other Companies
Frequently Asked Questions
- What is Kailera Therapeutics 's change in accrued liabilities?
- Kailera Therapeutics (KLRA) reported change in accrued liabilities of $9.38M in Q1 2026.
- What does change in accrued liabilities mean?
- The net change in expenses that have been recognized but not yet paid.